These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8839835)

  • 1. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
    Molldrem J; Dermime S; Parker K; Jiang YZ; Mavroudis D; Hensel N; Fukushima P; Barrett AJ
    Blood; 1996 Oct; 88(7):2450-7. PubMed ID: 8839835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
    Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
    Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
    St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
    Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
    Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
    Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
    Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
    Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
    Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
    Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.
    Fujiwara H; El Ouriaghli F; Grube M; Price DA; Rezvani K; Gostick E; Sconocchia G; Melenhorst J; Hensel N; Douek DC; Barrett AJ
    Blood; 2004 Apr; 103(8):3076-83. PubMed ID: 15070688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based vaccines in patients with hematological malignancies.
    Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
    Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope.
    Andersen RS; Wenandy L; Sørensen RB; thor Straten P; Andersen MH
    Leukemia; 2008 Mar; 22(3):668-9. PubMed ID: 17805325
    [No Abstract]   [Full Text] [Related]  

  • 15. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.
    Scheibenbogen C; Letsch A; Thiel E; Schmittel A; Mailaender V; Baerwolf S; Nagorsen D; Keilholz U
    Blood; 2002 Sep; 100(6):2132-7. PubMed ID: 12200377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.
    Kurokohchi K; Akatsuka T; Pendleton CD; Takamizawa A; Nishioka M; Battegay M; Feinstone SM; Berzofsky JA
    J Virol; 1996 Jan; 70(1):232-40. PubMed ID: 8523531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
    Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
    Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.
    Sergeeva A; Alatrash G; He H; Ruisaard K; Lu S; Wygant J; McIntyre BW; Ma Q; Li D; St John L; Clise-Dwyer K; Molldrem JJ
    Blood; 2011 Apr; 117(16):4262-72. PubMed ID: 21296998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.